{"product_id":"borderline-ovarian-tumors-in-women-of-childbearing-age-balancing-cancer-care-and-fertility","title":"Borderline Ovarian Tumors in Women of Childbearing Age: Balancing Cancer Care and Fertility","description":"\u003cp\u003eBorderline ovarian tumors (BOTs) are slow-growing, low-malignancy tumors that account for about 15% of all epithelial ovarian cancers. Since more than one-third of cases occur in women under 40 who still want children, choosing between cancer safety and fertility preservation is one of the hardest decisions in gynecologic surgery. This review of the medical literature analyzes the best available evidence to help patients understand their options, from cystectomy (removing only the cyst) to salpingo-oophorectomy (removing the ovary and fallopian tube), and explains the real risks of recurrence, survival rates, and fertility outcomes that come with each choice.\u003c\/p\u003e\n\n\u003ch1\u003eBorderline Ovarian Tumors in Women of Childbearing Age: Balancing Cancer Care and Fertility\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Are Borderline Ovarian Tumors?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#understanding-bots\"\u003eUnderstanding the Two Main Tumor Types\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgical-approach\"\u003eThe Surgical Approach: Staging, Frozen Section, and Laparoscopy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#adnexal-surgery\"\u003eAdnexal Surgery: Which Operation Is Best?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#disease-recurrence\"\u003eDisease Recurrence: What Are the Real Numbers?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fertility-outcomes\"\u003eFertility Outcomes After Fertility-Sparing Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pregnancy\"\u003eBorderline Ovarian Tumors During Pregnancy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusion\"\u003eConclusion: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eBorderline ovarian tumors have excellent survival: about 95% at 5 years for stages I–III, and over one-third occur in women under 40.\u003c\/li\u003e\n\u003cli\u003eFertility-sparing surgery preserves the uterus and ovary tissue and does not appear to affect overall survival, but it does increase relapse risk.\u003c\/li\u003e\n\u003cli\u003eRecurrence rates are higher after cystectomy (30.3%) than after removing one ovary (11%) or both ovaries (1.7%) in a French study.\u003c\/li\u003e\n\u003cli\u003eMost serous tumor recurrences are borderline again and can be treated with repeat conservative surgery; mucinous recurrences are more often invasive.\u003c\/li\u003e\n\u003cli\u003eFollow-up in the first two years is important because most recurrences happen then, but relapses can occur up to 15 years later.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Are Borderline Ovarian Tumors?\u003c\/h2\u003e\n\n\u003cp\u003eBorderline ovarian tumors (BOTs) are a group of growths that sit somewhere between benign cysts and full ovarian cancer. Doctors also call them tumors of \"low malignant potential.\" They are defined by abnormal cell growth (epithelial proliferation) and cell irregularity (nuclear atypia), but they lack the destructive tissue invasion seen in true cancers. In plain terms: they can spread and come back, but they behave far less aggressively than ovarian carcinoma.\u003c\/p\u003e\n\n\u003cp\u003eThese tumors account for approximately \u003cstrong\u003e15% of all epithelial ovarian cancers\u003c\/strong\u003e. The good news is that in nearly \u003cstrong\u003e80% of cases, the diagnosis is made at stage I\u003c\/strong\u003e, meaning the tumor is still confined to the ovary. Fewer than \u003cstrong\u003e1% of women are diagnosed at stage IV\u003c\/strong\u003e, the most advanced stage.\u003c\/p\u003e\n\n\u003cp\u003eBecause more than a third of BOTs occur in women younger than 40 who wish to preserve their childbearing potential, the question of conservative surgical management — treatment that saves the uterus and at least some ovarian tissue — has become critically important.\u003c\/p\u003e\n\n\u003ch3\u003eSurvival Statistics: The Outlook Is Favorable\u003c\/h3\u003e\n\n\u003cp\u003eSurvival rates for BOTs are very encouraging. For women with FIGO stage I–III disease, overall survival is \u003cstrong\u003e95% at 5 years and 90% at 10 years\u003c\/strong\u003e. Even at stage IV, survival is nearly \u003cstrong\u003e77%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003ePeritoneal spread (tumor cells reaching the lining of the abdomen) is present in about \u003cstrong\u003e10% of BOTs\u003c\/strong\u003e. These implants are divided into two categories:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-invasive implants\u003c\/strong\u003e (nearly 85% of cases): mortality rate of \u003cstrong\u003e4.7%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInvasive implants\u003c\/strong\u003e (the remaining 15%): mortality rate of \u003cstrong\u003e34%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese numbers show why the distinction between invasive and non-invasive spread matters so much for treatment planning and prognosis.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe authors performed an electronic database search of PubMed, Medline, and Embase up to April 2022. They developed a search algorithm incorporating the following medical terms: \"borderline ovarian tumors,\" \"low malignant potential,\" \"conservative surgery,\" \"fertility-sparing surgery,\" \"laparoscopy,\" \"invasive implants,\" \"micropapillary patterns,\" and \"recurrence.\"\u003c\/p\u003e\n\n\u003cp\u003eAll pertinent articles evaluating diagnostic and therapeutic approaches centered on fertility-sparing treatment were included. The researchers considered all original studies, meta-analyses, systematic reviews, and case reports published in English. They also systematically reviewed reference lists to identify additional studies for this narrative review.\u003c\/p\u003e\n\n\u003ch2 id=\"understanding-bots\"\u003eUnderstanding the Two Main Tumor Types\u003c\/h2\u003e\n\n\u003cp\u003eThe vast majority of BOTs have either serous or mucinous histotypes (cell types seen under the microscope). Knowing which type a patient has is essential for choosing the right surgical strategy. Other rare types (\u003cstrong\u003eless than 5%\u003c\/strong\u003e) include clear cell, endometrioid, and Brenner tumors.\u003c\/p\u003e\n\n\u003ch3\u003eSerous Borderline Ovarian Tumors (sBOTs)\u003c\/h3\u003e\n\n\u003cp\u003eSerous tumors make up about \u003cstrong\u003etwo-thirds of all BOTs\u003c\/strong\u003e. They are bilateral (affect both ovaries) in \u003cstrong\u003e15%–25% of cases\u003c\/strong\u003e, and non-invasive peritoneal spread is present in \u003cstrong\u003e15%–40%\u003c\/strong\u003e of cases. The risk of invasive peritoneal spread in early-stage serous tumors is very low. Only in a small percentage of cases do the implants infiltrate the underlying tissue; according to the 2014 WHO classification, these are considered low-grade serous carcinoma.\u003c\/p\u003e\n\n\u003cp\u003eThere is also a variant called the \u003cstrong\u003emicropapillary\/cribriform pattern\u003c\/strong\u003e. Compared with typical serous tumors, this variant carries a higher rate of bilateral ovarian involvement, recurrence, and invasive peritoneal implants.\u003c\/p\u003e\n\n\u003ch3\u003eMucinous Borderline Ovarian Tumors (mBOTs)\u003c\/h3\u003e\n\n\u003cp\u003eMucinous tumors are the second most common subtype, accounting for \u003cstrong\u003e30%–50% of all BOTs\u003c\/strong\u003e. They are nearly always unilateral (one ovary only) and tend to be larger than serous tumors, with an \u003cstrong\u003eaverage diameter of 20 centimeters\u003c\/strong\u003e (about the size of a grapefruit or larger).\u003c\/p\u003e\n\n\u003cp\u003ePatients with mucinous tumors relapse less frequently than those with serous disease. However, when an extraovarian relapse does occur, the risk of invasive recurrence and possible death is \u003cstrong\u003ehigher\u003c\/strong\u003e. Because of this, unilateral salpingo-oophorectomy (removing one ovary and its tube) is often the recommended surgery for mucinous tumors.\u003c\/p\u003e\n\n\u003ch3\u003eQuick Comparison Table: Serous vs. Mucinous BOTs\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevalence:\u003c\/strong\u003e Serous — about two-thirds of all BOTs; Mucinous — more than one-third\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival rate:\u003c\/strong\u003e Serous — around 97%; Mucinous — around 94%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Serous — often bilateral; Mucinous — nearly always unilateral\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeritoneal spread:\u003c\/strong\u003e Serous — 30% of cases; Mucinous — less frequent\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAverage diameter:\u003c\/strong\u003e Serous — 10 cm; Mucinous — 20 cm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelapse:\u003c\/strong\u003e Serous — more frequent; Mucinous — less frequent\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eType of recurrence:\u003c\/strong\u003e Serous — generally non-invasive (except micropapillary patterns); Mucinous — more often invasive\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReliability of frozen section:\u003c\/strong\u003e Serous — higher; Mucinous — lower\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"surgical-approach\"\u003eThe Surgical Approach: Staging, Frozen Section, and Laparoscopy\u003c\/h2\u003e\n\n\u003cp\u003eFertility-sparing surgery (FSS) is defined as the preservation of the uterus and ovarian tissue in one or both adnexa (the ovaries and fallopian tubes). More than a third of BOTs affect women of reproductive age who wish to preserve fertility. In early-stage disease, FSS is the mainstay of treatment, an alternative to radical surgery that removes all reproductive organs.\u003c\/p\u003e\n\n\u003cp\u003eFor advanced stages, the oncological safety of conservative treatment is less clear. As a general rule, patients with advanced-stage BOT should \u003cstrong\u003enot\u003c\/strong\u003e be offered conservative surgery if they have invasive implants, or if they have non-invasive implants that cannot be completely removed.\u003c\/p\u003e\n\n\u003ch3\u003eUterine Preservation and Fertility Options\u003c\/h3\u003e\n\n\u003cp\u003eRecent attention has focused on preserving the uterus even when saving healthy ovarian tissue is not feasible. Several options can help a woman build her family later:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOvarian tissue cryopreservation (freezing ovarian tissue) at the time of surgery\u003c\/li\u003e\n  \u003cli\u003eOocyte freezing (egg freezing)\u003c\/li\u003e\n  \u003cli\u003eOocyte donation\u003c\/li\u003e\n  \u003cli\u003eTransfer of frozen embryos obtained before surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNotably, FSS does not appear to affect overall survival. However, conservative treatment does increase the relapse rate. Patients must receive full, honest information about this risk before deciding.\u003c\/p\u003e\n\n\u003ch3\u003eThe Role of Frozen Section (Intraoperative Pathology)\u003c\/h3\u003e\n\n\u003cp\u003eThe frozen section (FS) is a technique where a tissue sample is rapidly frozen and examined under a microscope during the operation, helping the surgeon decide how much to remove in real time. While FS has a high diagnostic accuracy for benign and malignant ovarian tumors, it is notably less accurate for BOTs:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFrozen samples \u003cstrong\u003eunder-diagnose\u003c\/strong\u003e BOT as benign tumors in \u003cstrong\u003e25%–30%\u003c\/strong\u003e of cases\u003c\/li\u003e\n  \u003cli\u003eFrozen samples \u003cstrong\u003eimproperly identify\u003c\/strong\u003e BOT as carcinoma in \u003cstrong\u003e20%–30%\u003c\/strong\u003e of cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eExtra caution is needed with bulky (large) tumors, where the intraoperative histology can miss features like microinvasion, papillary variants, or intraepithelial carcinoma.\u003c\/p\u003e\n\n\u003ch3\u003eComplete Surgical Staging\u003c\/h3\u003e\n\n\u003cp\u003eAlthough formal surgical staging does not significantly change survival rates, an initial complete staging appears to significantly \u003cstrong\u003ereduce recurrence\u003c\/strong\u003e among BOT patients. A complete staging procedure includes:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eA complete exploration of the abdominal-pelvic peritoneal cavity\u003c\/li\u003e\n  \u003cli\u003ePeritoneal washing (flushing the abdomen and collecting the fluid for testing)\u003c\/li\u003e\n  \u003cli\u003eMultiple peritoneal biopsies\u003c\/li\u003e\n  \u003cli\u003eInfracolic omentectomy (removal of part of the omentum, a fatty apron in the abdomen)\u003c\/li\u003e\n  \u003cli\u003eComplete resection of all visible implants\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe complete removal of all peritoneal implants is a primary task, for both staging and treatment. Wide resection of surrounding tissue is needed so the pathologist can tell whether implants are invasive or non-invasive.\u003c\/p\u003e\n\n\u003cp\u003eSurgical restaging should be considered in patients with higher risk of malignancy (mucinous type, micropapillary variant) who had an incomplete visual exploration of the abdominal-pelvic peritoneum at their first surgery. Lymph node involvement carries low prognostic value, and removing lymph nodes (lymphadenectomy) has not been shown to improve survival. It is usually suggested only when lymph nodes are visibly enlarged or when invasive tumors are found on frozen examination.\u003c\/p\u003e\n\n\u003cp\u003eTaking a biopsy from a normal-appearing opposite ovary is not helpful for reducing recurrence risk. Instead, an accurate preoperative ultrasound and careful inspection during surgery are considered sufficient.\u003c\/p\u003e\n\n\u003ch3\u003eLaparoscopy vs. Open Surgery\u003c\/h3\u003e\n\n\u003cp\u003eMinimally invasive (laparoscopic) surgery has increased dramatically in recent years due to fewer complications, less blood loss, shorter recovery, and better cosmetic results. However, the choice of approach depends on tumor features, patient factors, and the surgeon's skill.\u003c\/p\u003e\n\n\u003cp\u003eOne key risk is tumor rupture during removal. Published data show that rupture happens more often during laparoscopic cystectomies, with tumor size as the main predictor:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIn a retrospective study of \u003cstrong\u003e105 patients\u003c\/strong\u003e, tumor rupture was significantly more frequent during laparoscopy than during open surgery: \u003cstrong\u003e29.5% vs. 13.1% (p = 0.038)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eAnother retrospective analysis found that an adnexal mass larger than \u003cstrong\u003e10 cm\u003c\/strong\u003e in maximum diameter carried a \u003cstrong\u003e4-fold higher risk of surgical spillage\u003c\/strong\u003e with the laparoscopic approach: \u003cstrong\u003e54.5% vs. 12.1%\u003c\/strong\u003e compared with open surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRupture of an intact tumor during removal can change the FIGO stage and affect recurrence risk, regardless of surgical method. Despite this, laparoscopy has not shown a negative impact on recurrence rate, survival, or surgical feasibility when performed carefully. The conversion rate from laparoscopy to open surgery is reported at approximately \u003cstrong\u003e30%\u003c\/strong\u003e for BOT patients. If surgery without risk of rupture is possible, the laparoscopic approach is considered feasible, safe, and recommended over laparotomy.\u003c\/p\u003e\n\n\u003cp\u003eRobotic surgery is another feasible alternative, but haptic feedback (the sense of touch that helps the surgeon measure tissue tension and avoid cyst rupture) is only present in some robotic platforms. Prospective randomized studies are still needed to define its role. Ultra-minimally invasive \"mini-laparoscopy\" using 2.4 mm needleoscopic instruments has also been described as a beneficial tool in borderline disease, though data remain limited to case reports.\u003c\/p\u003e\n\n\u003ch2 id=\"adnexal-surgery\"\u003eAdnexal Surgery: Which Operation Is Best?\u003c\/h2\u003e\n\n\u003cp\u003eThere are no clear international guidelines on the optimal fertility-sparing procedure. For stage I disease, surgical options include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eUnilateral or bilateral cystectomy (removing only the cyst, leaving the ovary)\u003c\/li\u003e\n  \u003cli\u003eUnilateral salpingo-oophorectomy (USO, removing one ovary and one fallopian tube)\u003c\/li\u003e\n  \u003cli\u003eUSO plus contralateral cystectomy (removing one full side and only the cyst on the other side)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe histological subtype and the presence of poor-prognosis factors (microinvasion, micropapillary pattern, peritoneal implants) strongly influence which operation makes sense.\u003c\/p\u003e\n\n\u003ch3\u003eWhat the Data Show for Different Operations\u003c\/h3\u003e\n\n\u003cp\u003eA large French multicenter study of \u003cstrong\u003e313 patients with stage I BOTs\u003c\/strong\u003e found these recurrence rates by surgery type:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAfter cystectomy: \u003cstrong\u003e30.3%\u003c\/strong\u003e recurrence\u003c\/li\u003e\n  \u003cli\u003eAfter unilateral salpingo-oophorectomy: \u003cstrong\u003e11%\u003c\/strong\u003e recurrence\u003c\/li\u003e\n  \u003cli\u003eAfter bilateral salpingo-oophorectomy: \u003cstrong\u003e1.7%\u003c\/strong\u003e recurrence\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA recent systematic review confirmed these results: the recurrence rate correlates with the type of conservative surgery, with the highest rate after cystectomy.\u003c\/p\u003e\n\n\u003cp\u003eHowever, not all studies agree. Palomba and colleagues reported that bilateral cystectomy (compared with USO plus contralateral cystectomy in patients with bilateral disease, mainly serous subtype) \u003cstrong\u003eincreases the fertility rate without increasing the recurrence rate\u003c\/strong\u003e. A meta-analysis by Vasconcelos and colleagues confirmed this: in bilateral serous BOT, USO plus contralateral cystectomy had no advantage over bilateral cystectomy in terms of recurrence: \u003cstrong\u003e26.1% vs. 25.6%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe authors' practical conclusion: whenever cystectomy is chosen, the patient should receive careful counseling about a possibly higher risk of local and peritoneal recurrence compared with salpingo-oophorectomy.\u003c\/p\u003e\n\n\u003ch3\u003eWhich Operation for Which Tumor?\u003c\/h3\u003e\n\n\u003cp\u003eBecause most mucinous BOTs carry a higher risk of invasive recurrence, and because they can coexist with invasive cancer areas, \u003cstrong\u003eunilateral salpingo-oophorectomy is the preferred treatment\u003c\/strong\u003e for these tumors. Cystectomy is acceptable only for bilateral mucinous disease, or when a contralateral cystectomy is the only way to preserve fertility in a patient who previously had a salpingo-oophorectomy on the other side.\u003c\/p\u003e\n\n\u003cp\u003eFor serous BOTs, which are often bilateral and behave relatively benignly compared with mucinous tumors, the reproductive advantage of cystectomy over USO is still debated. The reproductive outcome appears similar between the two operations, but concerns about higher recurrence after cystectomy remain.\u003c\/p\u003e\n\n\u003cp\u003eFor bilateral serous BOT, cystectomy or unilateral salpingo-oophorectomy plus contralateral cystectomy is the \u003cstrong\u003eonly\u003c\/strong\u003e fertility-sparing option. The same applies to the rare patient who has already had a salpingo-oophorectomy on one side.\u003c\/p\u003e\n\n\u003ch2 id=\"disease-recurrence\"\u003eDisease Recurrence: What Are the Real Numbers?\u003c\/h2\u003e\n\n\u003cp\u003eConservative management has a significant impact on recurrence compared with radical surgery. The numbers are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRecurrence after conservative surgery: \u003cstrong\u003e5%–34%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eRecurrence after radical surgery: \u003cstrong\u003e3.2%–7%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eOverall risk of recurrence: \u003cstrong\u003e2%–24%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eRisk of invasive recurrence: \u003cstrong\u003e0.5%–3.8%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRecurrences can appear in the remaining ovary after cystectomy, in the contralateral ovary, or as extraovarian peritoneal and omental implants.\u003c\/p\u003e\n\n\u003ch3\u003eWhen Do Recurrences Happen?\u003c\/h3\u003e\n\n\u003cp\u003eRecurrence rates are time-dependent. About \u003cstrong\u003e25% of recurrences are diagnosed after 5 years\u003c\/strong\u003e, and relapses can occur as late as \u003cstrong\u003e15 years after surgery\u003c\/strong\u003e. Recurrences are most frequent during the \u003cstrong\u003efirst two postoperative years\u003c\/strong\u003e, making close follow-up critical during this period. Follow-up typically includes systematic clinical examination, transvaginal ultrasound, and serum markers.\u003c\/p\u003e\n\n\u003cp\u003eUnfortunately, only about \u003cstrong\u003e40% of women with stage I BOTs\u003c\/strong\u003e have elevated levels of the CA125 blood marker, so many patients cannot rely on this test alone for early detection of relapse.\u003c\/p\u003e\n\n\u003ch3\u003eRecurrence by Tumor Type\u003c\/h3\u003e\n\n\u003cp\u003eMost serous BOT recurrences are, in large part, borderline tumors again — not full cancers. These can often be treated safely with repeated conservative surgery in patients who still want children. Mucinous tumors relapse less often, but when they do, the recurrence is more likely to be invasive.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Risk Features: Microinvasion and Micropapillary Patterns\u003c\/h3\u003e\n\n\u003cp\u003eSeveral factors identify patients at higher risk of invasive recurrence, although not all experts agree on every factor:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEarly stage by FIGO classification\u003c\/strong\u003e is a known independent risk factor for recurrence (and may seem counterintuitive — the authors note higher rates of extraovarian recurrence in stage IC3 and grade 3 tumors, which should be recognized as limits of conservative management for oncological safety).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicropapillary pattern\u003c\/strong\u003e in serous tumors is associated with advanced stage, bilateral ovarian involvement, and invasive recurrence. Notably, serous BOTs with a micropapillary pattern but no invasive implants (stage I) or with only non-invasive implants (stages II and III) may have the same good prognosis as typical serous BOTs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStromal microinvasion\u003c\/strong\u003e (tumor cells invading the supportive tissue to a depth of 5 mm or less) is a predictor of relapse.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eThe Numbers Behind Microinvasion\u003c\/h3\u003e\n\n\u003cp\u003eOne case series followed \u003cstrong\u003e171 borderline mucinous tumors\u003c\/strong\u003e and found that the microinvasive pattern carried a significantly higher recurrence rate (p = 0.013):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWithout microinvasion: \u003cstrong\u003e1.7% recurrence\u003c\/strong\u003e (2 of 116 cases)\u003c\/li\u003e\n  \u003cli\u003eWith microinvasion: \u003cstrong\u003e14.3% recurrence\u003c\/strong\u003e (4 of 28 cases)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA retrospective study of \u003cstrong\u003e902 BOT patients\u003c\/strong\u003e confirmed this finding. Patients with microinvasive BOT had a significantly higher recurrence rate than those without: \u003cstrong\u003e17.4% vs. 7.8%\u003c\/strong\u003e (odds ratio 3.55, 95% CI 1.091–11.59, p = 0.03). Stromal microinvasion was also a prognostic factor for significantly shorter disease-free survival: \u003cstrong\u003e26.7 months vs. 11.9 months (p = 0.031)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eData from \u003cstrong\u003e209 patients\u003c\/strong\u003e showed that microinvasive BOTs recurred earlier than non-invasive BOTs, with a median time to recurrence of \u003cstrong\u003e10.5 months\u003c\/strong\u003e for microinvasive tumors versus \u003cstrong\u003e17 months\u003c\/strong\u003e for non-invasive ones. Unilateral salpingo-oophorectomy rather than cystectomy did not seem to prevent relapses in microinvasive disease — recurrences were recorded in \u003cstrong\u003e27%\u003c\/strong\u003e of patients even after this more extensive surgery. Encouragingly, overall survival did not differ significantly from BOTs without microinvasion.\u003c\/p\u003e\n\n\u003cp\u003eMicroinvasion frequently coexists with the micropapillary variant in serous tumors, which complicates efforts to determine each factor's exact role in recurrence. For young patients with these high-risk features, fertility-sparing surgery may still be a reasonable option, but only if an accurate, strict follow-up is possible.\u003c\/p\u003e\n\n\u003ch2 id=\"fertility-outcomes\"\u003eFertility Outcomes After Fertility-Sparing Surgery\u003c\/h2\u003e\n\n\u003cp\u003eStudies give mixed results on how fertility-sparing treatments affect ovarian function, and it remains unclear whether pregnancy outcomes depend on the specific procedure chosen (unilateral salpingo-oophorectomy versus ovarian cystectomy). What is clear is that ovarian surgery — especially a second operation — can reduce healthy ovarian tissue, increasing the risk of infertility. Postoperative adhesions (scar tissue) can also interfere with fallopian tube function.\u003c\/p\u003e\n\n\u003cp\u003eThat said, the news is largely positive: after fertility-sparing surgery, \u003cstrong\u003epregnancy outcomes are encouraging, and most pregnancies are achieved spontaneously as early as 3 months after surgery\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBecause of concerns about pregnancies complicated by recurrent disease, many physicians recommend delaying pregnancy until a sufficient follow-up period has passed after initial treatment. Little is known about how often BOTs occur or are managed during pregnancy itself, though expectant management appears safe if a recurrence is found during pregnancy.\u003c\/p\u003e\n\n\u003cp\u003eThere is no specific data on infertility treatment after conservative surgery for BOTs, and it is unclear whether fertility drugs affect recurrence rates. More research is needed, particularly because ovulation induction and in vitro fertilization (IVF) may be required to help these patients conceive.\u003c\/p\u003e\n\n\u003ch2 id=\"pregnancy\"\u003eBorderline Ovarian Tumors During Pregnancy\u003c\/h2\u003e\n\n\u003cp\u003eBOTs diagnosed during pregnancy appear to have more concerning features than those found in non-pregnant patients. Reports describe a higher incidence of advanced stage at presentation, a higher percentage of mucinous BOTs with intraepithelial carcinoma and microinvasion, and more serous BOTs with micropapillary components.\u003c\/p\u003e\n\n\u003cp\u003eManagement data during pregnancy are limited, based mostly on case reports. Standardized treatment strategies are therefore difficult to create, and current practice follows the gold-standard treatment for non-pregnant women. The authors advise:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eClose surveillance to exclude signs of malignant transformation, such as rapid tumor enlargement, abnormal vascularization, or the presence of solid tissue within the tumor.\u003c\/li\u003e\n  \u003cli\u003eDelivery in a tertiary center specialized in gynecologic oncology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause performing complete staging at the initial surgery is technically difficult in pregnancy, some patients may need a postpartum completion of staging, a debulking procedure, or possibly adjuvant chemotherapy.\u003c\/p\u003e\n\n\u003ch2 id=\"conclusion\"\u003eConclusion: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFertility-sparing surgery is a well-established strategy for patients with BOTs who want to preserve fertility. The procedure offers an excellent reproductive outcome and long-term survival in the vast majority of cases.\u003c\/p\u003e\n\n\u003cp\u003eInvasive recurrences remain one of the main concerns with conservative management, which is why the choice of surgical procedure must be individualized. The balance between accurate staging and optimal fertility outcomes requires honest counseling about the risks and benefits of each option.\u003c\/p\u003e\n\n\u003cp\u003eThe bottom line: a woman diagnosed with a borderline ovarian tumor has an excellent chance of long-term survival and, in many cases, of having a child. The key is working with a specialized gynecologic oncology team to choose the approach that fits her specific tumor type, stage, and fertility goals.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a narrative review of existing literature, not a new clinical trial. The authors note several specific gaps in the evidence:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eProspective randomized studies are still needed to determine the relevance of robotic surgery in this context.\u003c\/li\u003e\n  \u003cli\u003eThe oncological safety of conservative treatment in advanced stages of BOTs has still to be clarified.\u003c\/li\u003e\n  \u003cli\u003eFindings are inconclusive about the impact of fertility-sparing treatments on ovarian function.\u003c\/li\u003e\n  \u003cli\u003eIt is unknown whether pregnancy outcomes are determined by the type of conservative approach used.\u003c\/li\u003e\n  \u003cli\u003eThere is no specific data on the management of infertility after conservative treatment, and the impact of fertility drugs on recurrence remains unclear.\u003c\/li\u003e\n  \u003cli\u003eData on BOTs during pregnancy are based mostly on case reports, making standardized recommendations difficult.\u003c\/li\u003e\n  \u003cli\u003eThe frequency and types of exams to perform during follow-up surveillance are not firmly established.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the evidence reviewed, here is what patients should discuss with their care team:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your tumor type.\u003c\/strong\u003e Ask whether your tumor is serous or mucinous, and whether any high-risk features (microinvasion, micropapillary pattern) were found. This strongly influences which surgery is safest.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the recurrence trade-off.\u003c\/strong\u003e Cystectomy offers the best fertility preservation but carries a higher recurrence risk (up to 30.3% in one large study) compared with salpingo-oophorectomy (11%) or bilateral salpingo-oophorectomy (1.7%). Most recurrences are still borderline tumors, not invasive cancers, and can often be treated with repeat conservative surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect close follow-up, especially in the first two years.\u003c\/strong\u003e Recurrences are most frequent then, but can appear up to 15 years later. Follow-up usually combines clinical exams, transvaginal ultrasound, and CA125 blood tests — though remember CA125 is only elevated in about 40% of stage I patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about fertility options before surgery.\u003c\/strong\u003e Egg freezing, embryo freezing, or ovarian tissue cryopreservation may be available, especially if removal of both ovaries is being considered.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnancy plans can be realistic.\u003c\/strong\u003e Most pregnancies after fertility-sparing surgery occur spontaneously, often within months of surgery. Many doctors recommend a follow-up period before trying to conceive.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you are pregnant with a BOT, seek a tertiary center\u003c\/strong\u003e with gynecologic oncology expertise for delivery and ongoing management.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet a second opinion if your tumor was large or your first surgery was incomplete.\u003c\/strong\u003e Surgical restaging may be recommended for mucinous tumors or micropapillary variants when the first operation did not include full abdominal exploration.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a borderline ovarian tumor and how is it different from ovarian cancer?\u003c\/h3\u003e\n\u003cp\u003eA borderline ovarian tumor is a growth between a benign cyst and true ovarian cancer. It can spread and return, but lacks destructive tissue invasion. Most cases are diagnosed at stage I, and overall survival at 5 years is about 95% for stages I–III, so the outlook is usually good.\u003c\/p\u003e\n\u003ch3\u003eCan I still have children after treatment for a borderline ovarian tumor?\u003c\/h3\u003e\n\u003cp\u003eYes. Fertility-sparing surgery preserves the uterus and ovarian tissue. After such surgery, most pregnancies are achieved spontaneously, often within months. If both ovaries are removed, options like egg or embryo freezing before surgery, or ovarian tissue cryopreservation, may help. Discuss fertility plans with your care team before deciding on surgery.\u003c\/p\u003e\n\u003ch3\u003eWhat are the recurrence risks after cystectomy versus removing the whole ovary?\u003c\/h3\u003e\n\u003cp\u003eIn a large French study of stage I tumors, recurrence was about 30.3% after cystectomy (removing only the cyst), 11% after unilateral salpingo-oophorectomy (removing one ovary and tube), and 1.7% after bilateral salpingo-oophorectomy. Most recurrences are borderline tumors again, not invasive cancers, and may be treated with repeat surgery.\u003c\/p\u003e\n\u003ch3\u003eWhich operation is recommended for mucinous borderline ovarian tumors?\u003c\/h3\u003e\n\u003cp\u003eFor mucinous tumors, the preferred treatment is usually unilateral salpingo-oophorectomy, removing one ovary and its fallopian tube. This is because mucinous tumors can coexist with invasive cancer areas and, if they relapse outside the ovary, the recurrence is more likely to be invasive. Cystectomy is reserved for special situations.\u003c\/p\u003e\n\u003ch3\u003eHow often does the frozen section test make an incorrect diagnosis?\u003c\/h3\u003e\n\u003cp\u003eFrozen section is a rapid test done during surgery. For borderline ovarian tumors, it under-diagnoses them as benign in about 25%–30% of cases and incorrectly identifies them as carcinoma in about 20%–30% of cases. Extra caution is needed with large tumors, where microinvasion or other features might be missed.\u003c\/p\u003e\n\u003ch3\u003eIf a borderline ovarian tumor is found during pregnancy, what happens next?\u003c\/h3\u003e\n\u003cp\u003eManagement is based on the same treatment principles as in non-pregnant women. Close surveillance checks for signs of malignancy, and delivery is advised in a specialized gynecologic oncology center. Complete staging may be difficult during pregnancy, so some patients may need postpartum completion of staging or further surgery.\u003c\/p\u003e\n\u003ch3\u003eHow long after fertility-sparing surgery must I wait before trying to conceive?\u003c\/h3\u003e\n\u003cp\u003eMost pregnancies after fertility-sparing surgery occur spontaneously, often as early as 3 months after surgery. However, many physicians recommend delaying pregnancy until a sufficient follow-up period has passed to reduce concerns about recurrent disease. Ask your medical team for advice personalized to your tumor type and treatment.\u003c\/p\u003e\n\u003ch3\u003eWhen should a woman with a borderline ovarian tumor seek a second opinion before choosing fertility-sparing surgery?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth seeking if your tumor was large, your first surgery did not include full abdominal exploration, or pathology shows a mucinous or micropapillary pattern, since these features affect recurrence risk and whether restaging surgery is recommended. Frozen section analysis can be inaccurate in 25–30% of borderline tumor cases, so expert pathology review may change the diagnosis. Recurrence rates differ by operation: cystectomy up to 30.3%, salpingo-oophorectomy 11%, so confirming your surgical plan is essential. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e challenging management of borderline ovarian tumors BOTs in women\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Luigi Della Corte, Antonio Mercorio, Paolo Serafino, Francesco Viciglione, Mario Palumbo, Maria Chiara De Angelis, Maria Borgo, Cira Buonfantino, Marina Tesorone, Giuseppe Bifulco, and Pierluigi Giampaolino\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Surgery, section Obstetrics and Gynecological Surgery\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e Published 23 August 2022 | Accepted 09 August 2022 | Received 19 June 2022\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fsurg.2022.973034\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCitation:\u003c\/strong\u003e Della Corte L, Mercorio A, Serafino P, Viciglione F, Palumbo M, De Angelis MC, Borgo M, Buonfantino C, Tesorone M, Bifulco G and Giampaolino P (2022) The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age. Front. Surg. 9:973034. doi: 10.3389\/fsurg.2022.973034\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. The original study was an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY), which permits use, distribution, and reproduction provided the original authors and copyright owners are credited. Patients should always discuss their individual situation with their own medical team, as this article is educational and does not replace personalized medical advice.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47549380296860,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/borderline-ovarian-tumors-in-women-of-childbearing-age-balancing-cancer-care-and-fertility","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}